TriangleBalstilimab (NCT07595874)
Balstilimab trial for Advanced Colon Adenocarcinoma (NCT07595874). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with untreated, resectable colorectal cancer that is mismatch-repair-proficient or microsatellite-stable. It must be T4 or node-positive, without distant spread; eligible rectal cancers must not need radiation.
The idea: give botensilimab and balstilimab before surgery. They block CTLA-4 and PD-1 immune checkpoints, aiming to help immune cells attack cancer. Patients receive one botensilimab infusion and four balstilimab infusions over six weeks, then surgery. Researchers assess two-year disease-free survival.
This phase 2 study plans 100 patients. Pashtoon Kasi leads at City of Hope in Duarte, with 11 recruiting US sites.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.